Board Committees

Brian Kotzin has served as a member of our Board of Directors and as a chairperson of our research and development committee since May 7, 2024.

He is a former member of the board of directors at Vera Therapeutics, Inc., Rigel Pharmaceuticals, Inc. and Kyverna Therapeutics, Inc. He served as Senior Vice President for Nektar Therapeutics, Inc. from April 2017 to June 2023, and has held various leadership positions at Nektar Therapeutics, Inc., including serving as Chief Medical Officer and Head of Clinical Development from January 2021 to September 2021 and again from May 2022 to June 2023. He currently is the interim chief medical officer at Nektar Therapeutics, Inc. From 2004 to 2015, Dr. Kotzin was Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area at Amgen Inc., directing the global development efforts for product candidates in the inflammation area. During his employment at Amgen Inc, he also served as Vice President of Translational Sciences and Head of Medical Sciences from 2006 to 2011. Prior to entering the life sciences industry, Dr. Kotzin held several positions as a professor at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of inflammatory diseases. He has also held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical Immunology Societies.

Pamela Klein has served as a member of our Board of Directors since April 2016.

Since 2008, Dr. Klein has been a principal and founder of PMK BioResearch, a company offering strategic consulting in oncology drug development to corporate boards, management teams and the investment community. She has also been a venture partner in Ysios Capital Partners, SGIEC, S.A.U. since 2023. She currently serves as a member of the board of directors of several companies including Shasqi and Patrys Ltd; as well as various scientific advisor boards. In 2023, Dr. Klein also joined the boards of directors of Frontier Medicines Corp, Ona Therapeutics SL, and Sardona Therapeutics, Inc. Previously, Dr. Klein served on the board of directors of Sardona Therapeutics, Inc., F-Star Therapeutics, Inc. until March 2023, Jiya Acquisition Corp, and Spring Bank Pharmaceuticals, Inc. until its merger with F-Star Therapeutics in July 2020. Dr. Klein previously spent seven years at the National Cancer Institute as research director of the NCI-Navy Breast Center, after which she joined Genentech as vice president of development until 2001. She also served as chief medical officer for Intellikine, Inc., which was acquired by Takeda American Holdings.

Dr. David L. Lacey served as a Director of argenx from 2014 to 2021, when he transitions to an advisory role. He has been a biopharmaceutical consultant since 2011, where he advises academic institutions, biotechnology companies and venture capital firms.

From 1994 until his retirement in 2011, he held various positions, including Head of Discovery Research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/RANKL/RANK pathway, which led to the development of the anti-RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA).

He holds a Bachelor’s degree in biology and an M.D. from the University of Colorado, and has his board certification in anatomic pathology.

Dr. Hedley has served as Senior Scientific Fellow at the Broad Institute of Harvard and MIT since 2020 and became a Venture Partner at Third Rock Ventures in 2022. She currently sits on the boards of Eli Lilly, Veeva Systems, Centessa Pharmaceuticals, and Azalea Therapeutics. Previously, she was Co-Founder, Director, President, and COO of TESARO from 2010 to 2019, following leadership roles at Abraxis, Eisai, MGI Pharma, and Zycos, which she co-founded after completing her postdoctoral fellowship at Harvard.

Dr. Hedley advises several biotechnology companies and CEOs, chairs the Life Science Committee of the Boston Museum of Science, serves on the board of Women Innovating Together in Healthcare (WITH), and is a member of the Biotech CEO Sisterhood. She earned a Bachelor’s degree from Purdue University and a Ph.D. in Immunology from UT Southwestern.

Hans de Haard is a co-founder of argenx and served as Chief Scientific Officer until 2022 before he transitioned to be an Ambassador for our Immunology Innovation Program and a Board Advisor.  Hans is a serial pioneer of antibody platforms and has been active in the antibody engineering field since 1989, initially at AKZO Nobel and subsequently at the University of Maastricht where he created a large non-immune human Fab library that subsequently became a core asset of Dyax, yielding multiple therapeutic antibodies including ImClone products IMC-A12, IMC-1F8 and the recently approved anti-VEGFR2 antibody ramucirumab (formerly called IMC-1121B).

From 1998 to 2002 he was responsible for the discovery of llama VHH-based products at Unilever. Just prior to argenx, Hans was on the discovery team at Ablynx where he was responsible for setting up the Nanobody® discovery engine and played a central role in the development of the Nanoclone® methodology based on B cell selection.

Throughout his career, Hans has discovered numerous therapeutic antibody leads, seven of which are now progressing in the clinic. He holds a Master of Science in Biochemistry and a PhD in Molecular Immunology from the University of Maastricht. He is a Professor of Immunology at the University of Franche Comté.

Tim Van Hauwermeiren co-founded argenx in April 2008 and serves as the non-Executive Director and Chairman of the Board of Directors. He has been a member of the Board of Directors since July 2014.

Tim serves on the Board of Directors of Lexeo Therapeutics, Inc. and he has served on the boards for iTeos Pharmaceuticals Inc. and Aelin Therapeutics, Inc.

Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors, including at Ablynx and Procter & Gamble. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management.

Key Terms of Contract